argenx Expands Vyvgart Into Three New Indications: CIDP, MG, and ITP Rep Roles Now Overlapping

By FieldPulse Editorial · March 18, 2026

Tags: rare-disease, field-force, argenx

argenx now has FDA approval across gMG, CIDP, and ITP, creating overlapping rep coverage and quota complexity. The company released new territory alignment protocols in Q1 2026.

argenx has received FDA approvals for efgartigimod (Vyvgart) across three distinct indications — generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP) — with a fourth indication in bullous pemphigoid under FDA review as of early 2026.

The multi-indication expansion has created a complex field structure in which some reps carry overlapping patient populations across neurology and hematology.

For reps hired into the gMG franchise in 2022 and 2023, the CIDP and ITP approvals have brought both opportunity and organizational disruption.

Some territories previously covered by a single rep are now covered by two or three, with unclear account ownership and sometimes competing call activity.

argenx leadership has acknowledged the coordination challenge and released updated territory alignment protocols in Q1 2026, creating designated account ownership rules and shared CRM visibility to reduce conflict.

The protocols have received mixed reviews from the field.

From a compensation standpoint, the multi-indication structure has complicated quota setting.

Reps are carrying separate attainment targets for each indication and bonus calculations are indication-specific, leading to a scenario where a rep can be above target in two of three indications but still miss overall bonus threshold.

Despite organizational growing pains, argenx's neonatal Fc receptor (FcRn) platform is widely viewed as one of the most differentiated mechanisms in rare autoimmune disease, and field turnover remains low relative to the broader specialty pharma market.

Source: https://www.endpoints11.com/2026/03/18/argenx-vyvgart-multi-indication-field-force-coverage-overlap/